HARVESTING AUTOLOGOUS GROWTH FACTORS FOR SURGICAL USE

收获自体生长因子用于手术

• 批准号: 6446999
• 负责人: Don B. Olsen
• 金额: $ 9.99万
• 依托单位: HEMOGENESIS, LLC
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6446999
• 关键词: biotherapeutic agent; cell sorting; centrifugation; cytotoxicity; drug design /synthesis /production; growth factor; human tissue; platelets; protein purification; sample collection; surgery material /equipment; technology /technique development; wound healing

DESCRIPTION (provided by applicant): Recombinant and autologous growth factor healants are being utilized increasingly for clinical and surgical wound healing scenarios. Recombinant growth factors are therapeutically applied to heal intractable diabetic and venous ulcers, while autologous growth factors are used in major orthopedic applications such as spinal fusion and joint implants. However, the cost and/or inconvenience of the current growth factor-based products have impeded their widespread use. The future of surgical growth factor healants will thus depend on the ease with which autologous growth factors can be obtained, and significant cost reduction. Recognizing this, the applicants have designed a process for quick, convenient and relatively inexpensive intraoperative harvesting of autologous platelets with preserved growth factors. The novel system described in this proposal obviates the need for centrifugation, and it can, for the first time, enable routine harvesting of autologous growth factors from small volumes of blood during surgery. The harvesting of platelets by this process can allow the delivery of growth factors using a wide variety of approved substrates such as hydrogels, collagen compositions, alginates etc. The eventual goal of this concept is to make autologous growth factors readily available for use in a wide variety of soft and hard tissue surgical applications. PROPOSED COMMERCIAL APPLICATION: The proposed project will lead to the development of a convenient, quick and inexpensive process to isolate autologous growth factors that can be delivered to augment wound healing in various soft and hard tissue surgical procedures.

描述（由申请人提供）：重组和自体增长因子 治疗剂越来越多地用于临床和手术伤口 治愈方案。重组生长因子在治疗上应用于 治愈顽固性的糖尿病和静脉溃疡，而自体生长因子 用于主要骨科应用，例如脊柱融合和关节 植入物。但是，当前增长的成本和/或不便 基于因素的产品阻碍了它们的广泛使用。手术的未来 因此，生长因子的疗养剂将取决于自体的易用性 可以获得生长因子，并大幅降低成本。 认识到这一点，申请人为快速，方便设计了一个过程 自体血小板的术中相对廉价的术中收获 与保留的生长因子。该提案中描述的新型系统 消除了离心的需求，它可以首次启用 从少量血液中的自体生长因子的常规收获 手术期间。通过此过程收集血小板可以允许 使用多种认可的底物（例如 水凝胶，胶原蛋白成分，藻酸盐等 概念是使自体增长因子很容易在 各种各样的软组织手术应用。 拟议的商业应用：拟议的项目将导致一个方便，快速且廉价的过程开发，以隔离自体生长因子，以增加各种软组织外科手术程序中的伤口愈合。